CA2438519A1 - Emulsions and aqueous dispersions of phytosterols - Google Patents
Emulsions and aqueous dispersions of phytosterols Download PDFInfo
- Publication number
- CA2438519A1 CA2438519A1 CA002438519A CA2438519A CA2438519A1 CA 2438519 A1 CA2438519 A1 CA 2438519A1 CA 002438519 A CA002438519 A CA 002438519A CA 2438519 A CA2438519 A CA 2438519A CA 2438519 A1 CA2438519 A1 CA 2438519A1
- Authority
- CA
- Canada
- Prior art keywords
- phytosterol
- emulsifier
- aqueous phase
- fat
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000006185 dispersion Substances 0.000 title claims abstract description 54
- 229940068065 phytosterols Drugs 0.000 title claims abstract description 40
- 239000000839 emulsion Substances 0.000 title claims description 61
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 95
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 34
- 229930182558 Sterol Natural products 0.000 claims abstract description 29
- 150000003432 sterols Chemical class 0.000 claims abstract description 29
- 235000003702 sterols Nutrition 0.000 claims abstract description 29
- 235000010445 lecithin Nutrition 0.000 claims abstract description 21
- 239000000787 lecithin Substances 0.000 claims abstract description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 19
- 229940067606 lecithin Drugs 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims abstract description 10
- 235000013310 margarine Nutrition 0.000 claims abstract description 8
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000007762 w/o emulsion Substances 0.000 claims abstract description 5
- 239000003264 margarine Substances 0.000 claims abstract description 4
- 235000019197 fats Nutrition 0.000 claims description 66
- 239000012071 phase Substances 0.000 claims description 58
- 239000008346 aqueous phase Substances 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 51
- 230000003472 neutralizing effect Effects 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 26
- 150000003904 phospholipids Chemical class 0.000 claims description 23
- 239000002562 thickening agent Substances 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 16
- 235000004213 low-fat Nutrition 0.000 claims description 15
- 235000016709 nutrition Nutrition 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 235000010443 alginic acid Nutrition 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 6
- 229940072056 alginate Drugs 0.000 claims description 6
- 235000013365 dairy product Nutrition 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003349 gelling agent Substances 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 235000014438 salad dressings Nutrition 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000014156 coffee whiteners Nutrition 0.000 claims description 2
- 235000011850 desserts Nutrition 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 235000010746 mayonnaise Nutrition 0.000 claims description 2
- 239000008268 mayonnaise Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000011962 puddings Nutrition 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 abstract description 15
- 230000001804 emulsifying effect Effects 0.000 abstract description 9
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 60
- 239000000047 product Substances 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000003921 oil Substances 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 14
- -1 chalinosterol Chemical compound 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 10
- 229920000136 polysorbate Polymers 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 235000002378 plant sterols Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 235000013861 fat-free Nutrition 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019211 fat replacer Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940075999 phytosterol ester Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- MCWVPSBQQXUCTB-UHFFFAOYSA-N (24Z)-5alpha-Stigmasta-7,24(28)-dien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(=CC)C(C)C)CCC33)C)C3=CCC21 MCWVPSBQQXUCTB-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 235000019917 Oatrim Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- HCXVJBMSMIARIN-LWINXXIXSA-N Poriferasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-LWINXXIXSA-N 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- MCWVPSBQQXUCTB-OQTIOYDCSA-N avenasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC/C(=C/C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 MCWVPSBQQXUCTB-OQTIOYDCSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000012839 cake mixes Nutrition 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012777 commercial manufacturing Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 235000019964 ethoxylated monoglyceride Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000019823 konjac gum Nutrition 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000015036 low fat salad dressings Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000008291 lyophilic colloid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000019952 microparticulated protein Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000008449 regular salad dressings Nutrition 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/36—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/01—Other fatty acid esters, e.g. phosphatides
- A23D7/011—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/01—Other fatty acid esters, e.g. phosphatides
- A23D7/013—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/02—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by the production or working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/066—Chewing gum characterised by the composition containing organic or inorganic compounds characterised by the fat used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/327—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds characterised by the fatty product used, e.g. fat, fatty acid, fatty alcohol, their esters, lecithin, glycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Phytosterols can be dispersed at high concentrations in aqueous media by partial neutralization of the inherent phytosterol w/o emulsifying properties using a non-sterol emulsifier having a higher HLB value. A preferred non-sterol emulsifier is a lecithin preparation comprising lysolecithin. These low-viscosity aqueous phytosterol dispersions can be used to prepare blood cholesterol lowering, stable w/o emulsions such as spreads and margarine.
Description
Emulsions and aqueous dispersions of phytosterols Field of the Invention The present invention relates to edible compositions having an aqueous phase and comprising phytosterol(s) in the aqueous phase, to a method for preparing such compositions, and to the use of these compositions in preventing or treating hypercholesterolemia and other medical conditions.
Background of the Invention The cholesterol-lowering effects of dietary plant sterols have been recognized for over 50 years. In the intestinal lumen cholesterol is found in solution with other fats in micelles composed of bile salts, phospholipids, tri-, di- and monoglycerides, fatty acids and fat-soluble micronutrients. In the process of absorption, cholesterol in the micelles is transported across the intestinal lining and into the lymph. It is generally accepted that there are two possible mechanisms by which plant sterols can inhibit absorption of cholesterol from the small intestine: co-precipitation of cholesterol and plant sterols, and competition for space in mixed micelles.
According to the co-precipitation mechanism, when the poorly-absorbed plant sterols reach a critical concentration in the gut they precipitate out of solution, bringing cholesterol down with them. The precipitated crystalline cholesterol is insoluble and cannot be absorbed.
The alternative mechanism is related to the limited capacity in the mixed micelles for carrying cholesterol. Competition for this space by structurally similar plant sterols has the effect of restricting the amount of cholesterol that can be transported into the intestinal cells via the micelles.
The highly hydrophobic nature of phytosterols renders them insoluble and barely dispersible in aqueous media. For convenience, phytosterols tend to be added to the fat phase of fat-based food products. Health-conscious consumers wishing to benefit from the cholesterol-lowering effects of phytosterols are therefore forced to consume fat-rich foods, despite the health risks of a high fat diet.
Since phytosterols have high melting points (typically about 136-150°C) it is important to maintain a temperature of 80°C or higher during dissolution of phytosterols in fats or oils, in order to avoid recrystallisation of the phytosterols. Crystalline phytosterol imparts an unpleasant grainy, waxy texture to edible and topical products. However, at 80°C and above commonly used fats and oils are vulnerable to oxidation. Rancid oils and fats detract greatly from the organofeptic properties of food products in particular.
The problems associated with adding phytosterols to the fat phase are compounded in low fat, fat-based products. The amount of phytosterol capable of being dispersed in the fat phase of a fat-based emulsified product directly correlates with the amount of lipid in the product. Thus, when the lipid content is reduced to below a certain level it becomes technically impossible to incorporate enough phytosterol into an edible product to obtain a tangible health benefit. The problems posed by the need to disperse phytosterols in fat become more acute the lower the fat content of a fat-based product. Although the fat-solubility of phytosterols can be improved by esterification, this is not a satisfactory solution to the problem, since phytosterol esters are biologically less efficacious than non-esterified phytosterols. Furthermore, when phytosterol or phytosterol ester is distributed within the small volume lipid phase of a low fat emulsified product the taste of the product is adversely affected, since the high concentration of phytosterol in the fat leads to a waxy sensation in the mouth and on the tongue.
In view of the technical difficulties involved in adding phytosterols to fat in foods, and bearing in mind public demand for low-fat and fat-free products, it would be advantageous to find an effective means of dispersing or suspending phytosterols in aqueous media at high concentrations, thereby opening up the possibility of providing low fat or fat-free products containing phytosterols in a variety of formats.
Although the solubility of phytosterols in water has been shown to be improved to some extent through use of food-grade water-in-oil (w/o) emulsifiers such as lecithin, optionally in the presence of a coating material, the resulting dispersions are frequently very viscous, non-homogenous, have poor mouth-feel, and are unstable (liable to separate) and difficult to handle. There is a particular tendency for phytosterol in these dispersions to solidify. This can cause severe processing difficulties in the manufacture of phytosterol-containing products on an industrial scale. For example, heat and mechanical energy are applied in the preparation of w/o or o/w emulsions. Under these conditions of elevated temperature and vigorous mixing the presence of phytosterol in an emulsion promotes premature solidification, thereby causing blockages in the processing machinery.
The present invention concerns a new technique allowing unprecedentedly large amounts of phytosterol to be dispersed in an aqueous medium without causing adverse effects on mouth-feel. The resulting dispersions and emulsions made using these dispersions are stable, have tow viscosity, and are easy to handle during downstream processing steps.
This novel dispersion technique has broad applications not only within the food industry, but also to pharmaceutical manufacturing and to cosmetics.
Summary of the Invention In a first aspect of the invention there is provided a method of preparing a product comprising phytosterol dispersed in an aqueous phase, which comprises mixing particulate phytosterol with an aqueous medium in the presence of a non-sterol emulsifier having a HLB value higher than that of the phytosterol to create an aqueous phytosterol dispersion, such that the combined HLB value of the non-sterol emulsifier and the phytosterol in the aqueous phase does not exceed 8.
According to a second aspect of the invention there is provided a method of preparing an emulsified product comprising phytosterol dispersed in an aqueous phase, which comprises mixing particulate phytosterol with an aqueous phase, adding a non-sterol emulsifier having a HLB value of at least 7 to the aqueous phase and/or to a fat phase, and mixing together the aqueous phase and the fat phase to form an emulsion.
According to a third. aspect of the invention there is provided a composition obtainable by the preparative method of the invention.
Background of the Invention The cholesterol-lowering effects of dietary plant sterols have been recognized for over 50 years. In the intestinal lumen cholesterol is found in solution with other fats in micelles composed of bile salts, phospholipids, tri-, di- and monoglycerides, fatty acids and fat-soluble micronutrients. In the process of absorption, cholesterol in the micelles is transported across the intestinal lining and into the lymph. It is generally accepted that there are two possible mechanisms by which plant sterols can inhibit absorption of cholesterol from the small intestine: co-precipitation of cholesterol and plant sterols, and competition for space in mixed micelles.
According to the co-precipitation mechanism, when the poorly-absorbed plant sterols reach a critical concentration in the gut they precipitate out of solution, bringing cholesterol down with them. The precipitated crystalline cholesterol is insoluble and cannot be absorbed.
The alternative mechanism is related to the limited capacity in the mixed micelles for carrying cholesterol. Competition for this space by structurally similar plant sterols has the effect of restricting the amount of cholesterol that can be transported into the intestinal cells via the micelles.
The highly hydrophobic nature of phytosterols renders them insoluble and barely dispersible in aqueous media. For convenience, phytosterols tend to be added to the fat phase of fat-based food products. Health-conscious consumers wishing to benefit from the cholesterol-lowering effects of phytosterols are therefore forced to consume fat-rich foods, despite the health risks of a high fat diet.
Since phytosterols have high melting points (typically about 136-150°C) it is important to maintain a temperature of 80°C or higher during dissolution of phytosterols in fats or oils, in order to avoid recrystallisation of the phytosterols. Crystalline phytosterol imparts an unpleasant grainy, waxy texture to edible and topical products. However, at 80°C and above commonly used fats and oils are vulnerable to oxidation. Rancid oils and fats detract greatly from the organofeptic properties of food products in particular.
The problems associated with adding phytosterols to the fat phase are compounded in low fat, fat-based products. The amount of phytosterol capable of being dispersed in the fat phase of a fat-based emulsified product directly correlates with the amount of lipid in the product. Thus, when the lipid content is reduced to below a certain level it becomes technically impossible to incorporate enough phytosterol into an edible product to obtain a tangible health benefit. The problems posed by the need to disperse phytosterols in fat become more acute the lower the fat content of a fat-based product. Although the fat-solubility of phytosterols can be improved by esterification, this is not a satisfactory solution to the problem, since phytosterol esters are biologically less efficacious than non-esterified phytosterols. Furthermore, when phytosterol or phytosterol ester is distributed within the small volume lipid phase of a low fat emulsified product the taste of the product is adversely affected, since the high concentration of phytosterol in the fat leads to a waxy sensation in the mouth and on the tongue.
In view of the technical difficulties involved in adding phytosterols to fat in foods, and bearing in mind public demand for low-fat and fat-free products, it would be advantageous to find an effective means of dispersing or suspending phytosterols in aqueous media at high concentrations, thereby opening up the possibility of providing low fat or fat-free products containing phytosterols in a variety of formats.
Although the solubility of phytosterols in water has been shown to be improved to some extent through use of food-grade water-in-oil (w/o) emulsifiers such as lecithin, optionally in the presence of a coating material, the resulting dispersions are frequently very viscous, non-homogenous, have poor mouth-feel, and are unstable (liable to separate) and difficult to handle. There is a particular tendency for phytosterol in these dispersions to solidify. This can cause severe processing difficulties in the manufacture of phytosterol-containing products on an industrial scale. For example, heat and mechanical energy are applied in the preparation of w/o or o/w emulsions. Under these conditions of elevated temperature and vigorous mixing the presence of phytosterol in an emulsion promotes premature solidification, thereby causing blockages in the processing machinery.
The present invention concerns a new technique allowing unprecedentedly large amounts of phytosterol to be dispersed in an aqueous medium without causing adverse effects on mouth-feel. The resulting dispersions and emulsions made using these dispersions are stable, have tow viscosity, and are easy to handle during downstream processing steps.
This novel dispersion technique has broad applications not only within the food industry, but also to pharmaceutical manufacturing and to cosmetics.
Summary of the Invention In a first aspect of the invention there is provided a method of preparing a product comprising phytosterol dispersed in an aqueous phase, which comprises mixing particulate phytosterol with an aqueous medium in the presence of a non-sterol emulsifier having a HLB value higher than that of the phytosterol to create an aqueous phytosterol dispersion, such that the combined HLB value of the non-sterol emulsifier and the phytosterol in the aqueous phase does not exceed 8.
According to a second aspect of the invention there is provided a method of preparing an emulsified product comprising phytosterol dispersed in an aqueous phase, which comprises mixing particulate phytosterol with an aqueous phase, adding a non-sterol emulsifier having a HLB value of at least 7 to the aqueous phase and/or to a fat phase, and mixing together the aqueous phase and the fat phase to form an emulsion.
According to a third. aspect of the invention there is provided a composition obtainable by the preparative method of the invention.
According to a fourth aspect of the invention there is provided a composition having an aqueous phase comprising a stable dispersion of a phytosterol and a phospholipid emulsifier having a HLB value ? 7, wherein the weight ratio of phytosterol:phospholipid emulsifier in the aqueous phase is greater than 1:1, and the combined HLB
value of the phospholipid emulsifier and the phytosterol in the aqueous phase does not exceed 8.
According to another aspect of the invention there is provided an emulsion having an aqueous phase comprising a phytosterol and a lipid phase comprising a phospholipid emulsifier of HLB >_ 7.
In another aspect of the invention there is provided use of a neutralizing emulsifier to reduce the viscosity of an aqueous dispersion of phytosterol or of an emulsion comprising said aqueous dispersion, particularly where said dispersion comprises a thickening agent.
In a further aspect of the invention there is provided use of a neutralizing emulsifier to stabilize an emulsion comprising a fat phase and an aqueous phase comprising phytosterol, wherein the neutralizing emulsifier is in the aqueous phase or in the fat phase or distributed between the aqueous phase and the fat phase.
In yet another aspect of the invention there is provided use of a composition of the invention as a medicament.
In a further aspect of the invention there is provided use of a composition of the invention in the manufacture of a medicament or therapeutic nutritional formulation for the prevention or treatment of any of: elevated blood cholesterol levels, hypertriglyceridemia, coronary heart disease, diabetes, atherosclerosis, inflammation, osteoarthritis, breast cancer, colon cancer, and benign prostatic hyperplasia.
Description of the Figures Figure 1 is a flowchart depicting a preferred method of manufacture of a spread according to the invention.
value of the phospholipid emulsifier and the phytosterol in the aqueous phase does not exceed 8.
According to another aspect of the invention there is provided an emulsion having an aqueous phase comprising a phytosterol and a lipid phase comprising a phospholipid emulsifier of HLB >_ 7.
In another aspect of the invention there is provided use of a neutralizing emulsifier to reduce the viscosity of an aqueous dispersion of phytosterol or of an emulsion comprising said aqueous dispersion, particularly where said dispersion comprises a thickening agent.
In a further aspect of the invention there is provided use of a neutralizing emulsifier to stabilize an emulsion comprising a fat phase and an aqueous phase comprising phytosterol, wherein the neutralizing emulsifier is in the aqueous phase or in the fat phase or distributed between the aqueous phase and the fat phase.
In yet another aspect of the invention there is provided use of a composition of the invention as a medicament.
In a further aspect of the invention there is provided use of a composition of the invention in the manufacture of a medicament or therapeutic nutritional formulation for the prevention or treatment of any of: elevated blood cholesterol levels, hypertriglyceridemia, coronary heart disease, diabetes, atherosclerosis, inflammation, osteoarthritis, breast cancer, colon cancer, and benign prostatic hyperplasia.
Description of the Figures Figure 1 is a flowchart depicting a preferred method of manufacture of a spread according to the invention.
Detailed Description of the Invention It has not previously been reported that the inherent water-in-oil emulsifying properties of phytosterols contribute to the difficulties encountered in creating and using aqueous dispersions of phytosterols, and emulsions comprising such dispersions. We have now achieved surprising and dramatic technical improvements in the properties of compositions containing water-dispersed phytosterols by applying the preparative method of the invention, particularly in the context of emulsions containing a fat phase.
Through use of one or more neutralizing emulsifiers (e.g. any oil-in-water emulsifier) in the aqueous phase or in the fat phase in conjunction with phytosterol in the aqueous phase, preferably such that the combined HLB of emulsifying phytosterol plus added non-sterol emulsifiers) does not exceed 8, a surprisingly stable aqueous dispersion or emulsion of unexpectedly low viscosity is obtained.
It seems that the neutralizing emulsifier, whether in the aqueous phase, or the lipid phase of an emulsion, or distributed over both phases, manages to counteract some of the inherent w/o emulsifying activity of the phytosterol, preventing clumping together of phytosterol microparticles, formation of which is a major factor contributing to the viscosity and solidifying tendencies of phytosterols in aqueous media and in emulsions. The viscosity-reducing effect of the non-sterol emulsifier is particularly marked when a stabilizing thickener such as alginate is added to an aqueous dispersion containing phytosterol. Use of the neutralizing emulsifier enables high levels of thickener to be used without unduly increasing the viscosity. Thus, the rheological~properties of the dispersion are dramatically improved by use of a neutralizing emulsifier.
Furthermore, use of the neutralizing emulsifier counteracts the inherent instability of emulsions obtained by mixing a fat phase and a water phase containing high levels of phytosterol. The aqueous phytosterol dispersions of the invention can be used in the large-scale manufacture of emulsions containing high levels of phytosterol over a broad range of temperatures and under vigorous mixing conditions, without the drawback of breakdown of the emulsions and high viscosity.
Through use of one or more neutralizing emulsifiers (e.g. any oil-in-water emulsifier) in the aqueous phase or in the fat phase in conjunction with phytosterol in the aqueous phase, preferably such that the combined HLB of emulsifying phytosterol plus added non-sterol emulsifiers) does not exceed 8, a surprisingly stable aqueous dispersion or emulsion of unexpectedly low viscosity is obtained.
It seems that the neutralizing emulsifier, whether in the aqueous phase, or the lipid phase of an emulsion, or distributed over both phases, manages to counteract some of the inherent w/o emulsifying activity of the phytosterol, preventing clumping together of phytosterol microparticles, formation of which is a major factor contributing to the viscosity and solidifying tendencies of phytosterols in aqueous media and in emulsions. The viscosity-reducing effect of the non-sterol emulsifier is particularly marked when a stabilizing thickener such as alginate is added to an aqueous dispersion containing phytosterol. Use of the neutralizing emulsifier enables high levels of thickener to be used without unduly increasing the viscosity. Thus, the rheological~properties of the dispersion are dramatically improved by use of a neutralizing emulsifier.
Furthermore, use of the neutralizing emulsifier counteracts the inherent instability of emulsions obtained by mixing a fat phase and a water phase containing high levels of phytosterol. The aqueous phytosterol dispersions of the invention can be used in the large-scale manufacture of emulsions containing high levels of phytosterol over a broad range of temperatures and under vigorous mixing conditions, without the drawback of breakdown of the emulsions and high viscosity.
The mouth feel (bitterness, texture, grainy feel) of phytosterol in an aqueous dispersion or in the aqueous phase of an emulsion is improved through use of the neutralizing emulsifier, particularly when that emulsifier is phospholipid-based.
The method of the present invention makes it possible to include phytosterols at effective levels in the aqueous phase of a broad range of nutritional, cosmetic and pharmaceutical products, thereby opening up new formulation opportunities, such as low fat and fat free formulations.
In the present context the generic term "sterol" or "phytosterol" is intended to encompass any member of the family of free phytosterols (non-hydrogenated) and phytostanols, and esters or other derivatives thereof, and any mixture or combination thereof.
The phytosterols used in the invention may be chemically synthesized, or may be derived from natural sources, including plant sources such as avocado, soy, rice bran, tall oil pitch or soap, shea nut, coconut, and plant oils, for example rapeseed, soya, maize, sunflower and sesame oils. Some germ oils are very rich in phytosterols, wheat germ and oats being good examples. Non-exhaustive examples of plant sterols include sitosterol, stigmasterol, campesterol, brassicasterol, desmosterol, chalinosterol, poriferasterol, avenasterol, and clionasterol, and their corresponding stanols.
The phytosterols are provided in particulate powder form for use in preparing the dispersions of the invention. Dispersion is facilitated by using finely divided phytosterols, preferably where 95% of the particles have a size (diameter) of less than 1 OOp,m, preferably less than 30p,m and most preferably less than l5p,m. Usually, the particle size distribution will be such that 90% of the particles are in the range 100nm to 35p,m, more preferably 0.2 to 20p,m, and most preferably 0.5 to l5p.m. Particle mixtures with this size range can be prepared by standard milling techniques, such as by use of an air mill, high energy hammermill, disc mill, or air filtration mill. Optionally, the phytosterol is milled in the presence of sugar, and the powdered phytosterol/sugar mix is used in the preparation of sweetened food or nutritional products.
_7_ In the finished product (an aqueous dispersion, or an emulsion comprising the aqueous dispersion) the amount of phytosterol is preferred to be between about 0.5%
and 20% by weight of the product, more preferably 1 % to 15%, and most preferably 2% to 10% by weight, for example 3 to 8% by weight. In an emulsified product, the phytosterol in the aqueous phase may constitute 1-80 wt%, more preferably from 5-50 wt%, especially 7-25%, by weight of the aqueous phase.
The terms "neutralizing emulsifier", "neutralizing non-sterol emulsifier" and "o/w emulsifier"
are used interchangeably herein.
The neutralizing non-sterol emulsifier has a HLB (Hydrophilicity-Lipophilicity Balance) value which is higher than the HLB of the phytosterol in the aqueous phase, usually in the range 6-20, preferably 7 to 12. The HLB system is a scale used for describing the characteristics of a surface-active agent. Detailed information on the HLB system and determination of HLB values can be found in the Kirk-Othmer Encyclopedia of Chemical Technology, (3'a Ed.) 8: pp 910-918, which is incorporated herein by reference. Emulsifiers having HLB
values in the range 7 to 18, especially 8 to 18, are often termed oil in water (olw) emulsifiers. W/o emulsifiers have HLB values in the range 1-9, especially 1-6.
Since HLB
numbers are additive, the overall HLB value of a blend of emulsifiers of known HLB can easily be calculated.
In general, a single non-sterol emulsifier is used to neutralize the phytosterol.
Suitable neutralizing emulsifiers for use in the invention include phosphatides of HLB at least 7 (e.g. lysophosphatides), especially phosphoglycerides such as phospholipids and lysophospholipids. Lecithin preparations (E322) of suitably high HLB are particularly preferred, and among this group lecithin preparations containing at least 90 wt%, preferably at least 95 wt%, of acetone insoluble compounds (mostly phospholipids) are preferred.
Preparations of this sort have a low triglyceride content and are obtainable by dissolving away triglycerides from an impure lecithin preparation using acetone.
EmuItopT"" (Lucas Meyer) and SternPure ETM (Stern) are suitable lecithin emulsifiers.
Preferably, the lecithin preparations used in the invention will comprise at least 3 wt%, and more preferably at least wt%, of lysolecithin. Lecithin preparations comprising lysolecithin can be prepared from lecithin (e.g. soya lecithin or yolk lecithin) by enzymatic hydrolysis using snake venom _g_ phospholipase A2. A preferred lecithin preparation is one having a HLB value of between 8 and l 0, preferably 8-8.5.
Other neutralizing emulsifiers are [HLB values in brackets]: gelatin [9.8], sorbitan monolaurate [8.6], sodium oleate [18.0), potassium oleate [20.0], methylcellulose [10.5), acacia [12.0], tragacanth [13.2], triethanolamine oleate [12.0], polyoxyethylene monooleate [11.4], polyoxyethylene monostearate [11.6), polyoxyethylene monolaurate [13.1], polysorbates/Tweens [8 to 18] (specific examples being polyoxyethylene sorbitan monostearate (Tween 60/Tween 61 ) [14.9/9.6), polyoxyethylene sorbitan monooleate (Tinreen 80/Tween 81 ) [15/10), polyoxyethylene sorbitan monolaurate (Tween 20/Tween 21 ) [16.7/13.3), polyoxyethylene sorbitan monopalmitate (Tween 40) [15.6], polyoxyethylene sorbitan trioleate [11.0)), glyceryl esters [8-13], ethoxylated monoglycerides [12-14], sugar esters [>7; e.g. 11-15), citric acid esters of mono and diglycerides, LactemT"", CitremT"', DatemT"",and so on.
According to one embodiment of the invention when the phytosterol and neutralizing emulsifier are dispersed together in an aqueous medium, the HLB of the combination of all emulsifying components (including phytosterol and neutralizing emulsifier) in the aqueous dispersion exceeds that of the phytosterol component(s), and is <_8, preferably lying in the range of about 1 to' 8, more preferably between 3 and 6.
The amount of the non-sterol emulsifier in the aqueous dispersion, as a proportion of the finished product (e.g. an emulsion), is generally between 0.01 and 1 % by weight, and most preferably about 0.5%, such as between 0.25 and 0.45%. Phytosterol is preferably in weight excess relative to the non-sterol emulsifiers) in the aqueous dispersion. The relative weight proportions of phytosterol and non-sterol neutralizing emulsifiers present in the aqueous dispersion of the invention are optionally between 4:1 and 500:1, preferably between 7:1 and 50:1, and generally between 10:1 and 30:1.
According to another embodiment of the invention the phytosterol is dispersed in an aqueous medium, and~the neutralizing emulsifier is incorporated into a lipid medium, and an emulsion is prepared by mixing both media together. In this embodiment, too, the neutralizing emulsifier counteracts the low HLB of the phytosterol and stabilizes the emulsion formed when the aqueous phase and fat phases are mixed together. The _g_ phytosterol is preferably in weight excess relative to the non-sterol neutralizing emulsifier in the emulsified product, for instance in a dry weight ratio of 4:1 to 500:1, preferably 7:1 to 50:1, and generally 10:1 to 30:1. Optionally, the neutralizing emulsifier is distributed over both phases of the emulsion, preferably in the range 1:9 to 9:1 parts by weight (fat phase content:aqueous phase content).
In a preferred embodiment of the invention the aqueous phytosterol-containing dispersion is mixed directly with a lipid composition to create a very stable emulsion having a fat phase and a water phase, the phytosterols being primarily localized to the water phase. The emulsified fat based products created in accordance with the invention may be oil-in-water (o/w, or water continuous) or water-in-oil (w/o, or oil continuous) emulsions according to which emulsifiers are selected for use in preparing the emulsion. W/o emulsions are preferred. For the manufacture of enteral pharmaceutical and nutritional products, such as edible spreads, margarines, and icings/frostings it is usual to generate a wlo emulsion.
Salad dressings and infant formulas are generally o/w type emulsions.
Preparations for external application may be either o/w or w/o emulsions. Optionally, multiple emulsions of the w/o/w or o/w/o type can also be prepared.
fn an emulsion made in accordance with the invention the weight proportion of the aqueous phase:fat phase can vary according to the intended application of the emulsion. For edible compositions this ratio usually varies between 1:8 and 8:1. Regular yellow fat spreads and margarines contain up to 85% by weight of fat. Low fat spreads may contain 45-65% fat.
Very low fat spreads comprise 30% fat or lower. For regular salad dressings the level of fat is generally from 10-60%, more preferably from 15-40% by weight of the product. Low fat salad dressings can contain as tittle as 0-10% by weight of lipids.
In the emulsified products of the invention the fat phase preferably comprises one or more vegetable oils, such as sunflower oil, soybean oil, rapeseed oil, canola oil, corn oil, peanut/groundnut oil and the like. Dairy and other animal fat may also be used, Other lipid substances in the fat phase can include petroleum-derived waxes and oils. If desired the fat may be hydrogenated, fractionated and/or interesterified. For edible compositions it is preferred for the fat in the fat phase to comprise polyunsaturated fatty acids, PUFAs preferably contributing at least 30%, or more preferably at least 45%, of the fat phase by weight. Natural oils rich in PUFAs are the preferred source, some examples being sunflower, rapeseed, linseed, linola and/or soybean oils.
An advantage of the present invention is that it circumvents the need to add a wlo emulsifier to the fat phase of an oil continuous product, which is standard practice in commercial manufacturing of such products. The partially-neutralized inherent wlo emulsifying activity of the phytosterol aqueous phase suffices to create a stable w/o emulsion. Therefore, in one embodiment of the invention w/o emulsifiers are omitted from the lipid phase in the formation of an oil continuous fat-based product.
In certain circumstances emulsifiers may be employed in the fat phase, optionally in addition to the neutralizing phospholipid emulsifier, for example where an olw emulsion is prepared. Additional emulsifiers can include: anionic surfactants such as alcohol ether sulfates, alkyl sulfates, soaps and sulfosuccinates, sodium dodecyl sulfate (SDS), mono and diacylglycerides and derivatives thereof, e.g. AcetemT"", LactemT"", CitremT"", DatemT"";
cationic surfactants such as quaternary ammonium compounds; zwitterionic surfactants such as alkyl betaine derivatives; amphoteric surfactants such as fatty amine sulfates, difatty alkyl triethanolamine derivatives, phospholipids, lecithins, lysolecithins; and non-ionic surfactants such as the polyglycol ether derivatives of aliphatic or cycioaliphatic alcohols, saturated fatty acids and alkylphenols, water-soluble polyethyleneoxy adducts onto polypropylene glycol and alkyl polypropylene glycol, nonylphenol polyethoxyethanols, castor oil polyglycol ethers, polypropylene/polyethylene oxide adducts, tributylphenoxy-polyethoxyethanol, polyethylene glycol, octylphenoxy-polyethoxyethanol, lanolin alcohols, polyethoxylated (POE) alkyl phenols, POE fatty amides, POE fatty alcohol ethers, POE fatty amines, POE fatty esters, poloxamers (7-19), POE glycol monoethers (13-16), polysorbates and sorbitan esters, and glyceroglycolipids. In a preferred embodiment the fat phase of an emulsion made according to the invention comprises mono- and diglycerides.
Optionally, the emulsifier added to the fat phase is phytosterol. Thus, in accordance with the present invention it is possible to provide a finished edible composition containing large amounts of phytosterol distributed over both phases.
The amount of emulsifier required to be added to the fat phase varies according to the identity of the emulsifier, the type of emulsion, the material to be emulsified and the presence of stabilizing ingredients, but generally lies in the range 1-20% by weight of the lipid. For instance, the emulsion may comprise 0.05 to 1 %, preferably 0.05 to 0.5% by weight of mono and diglycerides. Exact amounts for particular applications can easily be determined by the skilled person. These will usually not need to be as high as levels used in conventional margarine manufacture, for instance, since their presence is only required where the emulsifying power of the partially neutralized phytosterols is insufficient to stabilize the emulsion.
As emulsion stabilizers, gelling agents, fat replacers and thickeners it is possible to use any conventional products suited for these purposes, especially those permitted for use in food products. Examples include, but are not limited to, lyophilic colloids such as polysaccharides including acacia gum, agar, alginic acid, carrageenan, guar gum, gellan gum, carob gum, konjac gum, karaya gum, tragacanth, locust bean gum, xanthan gum, cellulose gums, gel-forming starches (e.g. from corn, amaranth, oats, tapioca, rice and potato), modified food starches, polydextrose, maltodextrin, cyclodextrins, pectin, cellulose and its methylated derivatives, microcrystalline cellulose (MCC), inulin, oatrim, curdlan;
amphoterics (e.g.
gelatin); fibers; proteins or peptides (e.g. Microparticulated Protein Product MPP or whey protein-based thickeners); and synthetic or semi-synthetic polymers (e.g.
carbomer resins, cellulose ethers, carboxymethyl cellulose (CMC), carboxymethyf chitin, polyethylene glycol-n (ethylene oxide polymer H(OCH2CH2)"OH); finely divided solids iricluding clays (e.g.
attapulgite, bentonite, hectorite, kaolin, magnesium aluminium silicate and montmorillonite), microcrystalline cellulose oxides and hydroxides (e.g. aluminium hydroxide, magnesium hydroxide and silica); and cybotactic promoters/gellants including amino acids, lecithin and other phospholipids arid poloxamers.
Maltodextrin and/or alginate are the preferred stabilizers for addition to the aqueous phytosterol dispersion.
The amount of emulsion stabilizer/thickener to be included in the compositions of the invention depends on the consistency desired in the end product. Usual amounts lie in the range 0 to 30%, preferably 0.1 to 25% based on the weight of the aqueous phase of the product.
In a preferred procedure for preparing an aqueous dispersion in accordance with the invention, the phytosterol is provided in particulate, powder form and pre-mixed with other powdered ingredients (excluding the non-sterol emulsifier and any thickener), before addition of the 'pre-mix to hot water (60°C to 85°C) or other aqueous medium. The powdered non sterol (olw) emulsifier is then added to the aqueous medium containing the phytosterol.
Alternatively, the powdered phytosterol and powdered non-sterol (o/w) emulsifier are added together (e.g. as a pre-mix, or simultaneously) to the heated aqueous medium.
Once all the emulsifying ingredients are well dispersed it is possible to add thickening agents to the mix.
Addition of the phytosterols to the aqueous medium should be slow. Other optional components of the aqueous medium include gelling agents, fat replacers, and the like. The phytosterol-emulsifier complex in the aqueous medium is prepared by vigorous mixing, such as high shear mixing, e.g. by stirring, by turbine agitation, by propeller agitation, by microfluidization, by use of a centrifugal pump in standard Ventouri equipment, by use of a colloid mill or ball mill, by homogenization, by vortexing, by sonicating or by passing through a small orifice (e.g. in a French press).
Preferably, the aqueous medium comprising phytosterol and non-sterol (o/w) emulsifier is maintained at a temperature of between 60 and 100°C, generally about 80°C, and stirred until the phytosterol is evenly dispersed. At this point a milky suspension is obtained. The dispersion is kept under continuous agitation and, optionally, further water-soluble or water-dispersible ingredients are added to the suspension at this point: for example milk powder or protein, vegetable protein, colorings, flavorings, acidulants, preservatives, vitamins, salts, and so on. The aqueous phytosterol dispersion/suspension is phase-stable. This generally means, for example, that no phase separation is visible after at least 5 minutes, preferably after at least 30 minutes, and more preferably after at least 2 hours.
The aqueous dispersion may be used as such in preparing any liquid food, beverage, topical formulation or medicament. Alternatively the aqueous dispersion may be dried, for example by lyophilization or spray-drying, and then used in powdered form in a variety of applications.
In another embodiment of the invention the aqueous dispersion is employed (usually without an intermediate drying step) in the manufacture of an emulsified product comprising a fat phase and a water phase. W/o or o/w emulsions of this type can be prepared by any technique known in the art.
When the non-sterol neutralizing emulsifier is to be added to the fat phase of an emulsion it is melted into the fat blend that contains all the other fat ingredients, which is subsequently mixed with a phytosterol-containing aqueous phase (optionally prepared as described above).
According to a preferred process an aqueous dispersion of phytosterol (with or without the neutralizing non sterol emulsifier) is mixed with pre-heated lipid (oil or fat). Preheating is carried out at 50-60°C (preferably about 55°C). The pre-heated lipid comprises the non-sterol neutralizing emulsifier of the invention if none is already present in the aqueous dispersion or in addition to that added to the aqueous dispersion, and sometimes other emulsifiers which are lipid-soluble, such as lecithin, monoglycerides and diglycerides. An emulsion is created by mixing together the aqueous blend with the fat blend.
Further processing of the emulsion depends on the intended use of the emulsion. In the preparation of margarines, spreads and the like, the emulsifying step is followed by pasteurization, crystallisation and filling, which are standard procedures in,the art.
The lipid used to make the emulsions may comprise additional fat-soluble components which are customary additives in the art, for example stabilizers, coloring agents, flavoring agents, pH regulators, vitamins (e.g. vitamins A & D), salts, anti-bacterial agents, antioxidants and preservatives. In the case of spreads and margarines the preferred antioxidants are tocopherols.
Emulsified w/o products made by the preparative method of the invention are particularly phase stable and can be stored and transported under demanding conditions without exhibiting a tendency to separate.
The nutritional product formats which are envisaged to incorporate the aqueous dispersion of the invention include: emulsified fat spreads or margarine, shortenings, cheese, mayonnaise, ice-cream, salad dressing, yoghurt, smoothies, chocolate, puddings, dairy desserts, coffee whitener, custards, dairy beverages, milk-shakes, icings, baked products, cake mixes, noodles, pasta, granola bars, soups, infant formulas, and the like.
Medical nutrition products comprising the dispersion of the invention include enteral and parenteral complete formula diets, in liquid form or lyophilized for later reconstitution, and medical feeding supplements. Products formulated for enteral feeding may be intended for tube feeding or for oral administration, either in hospitals or in the home.
The medical nutrition products may be formulated having regard to the needs of particular patient types, such as diabetics, heart disease patients, stroke patients, arthritis sufferers, cancer patients, and anyone at risk of developing these diseases.
The nutritional products according to the invention may be non-fat products, low fat products or very low fat products. By "tow fat" is generally meant a product, such as a yellow fat spread, comprising less than 45% (e.g. 35-40%), preferably less than 35%, by weight fat. A "very low fat" product has less than 30% by weight fat.
This invention makes possible the provision of phytosterols in oral pharmaceutical dosage forms, particularly solid forms; including tablets, capsules, dragees, granules, pellets, chews, solutions, syrups, lozenges, and powders. Parenteral emulsions can also be prepared for administration to severely-debilitated patients. Customary pharmaceutical excipients, diluents and stabilizers may be employed.
Topical cosmetic and pharmaceutical formulations incorporating the emulsions of the invention include salves, creams, foams, lotions, gels, soaps, shampoos, and the like.
The pharmaceutical,~food or drink products may be supplemented with other health-promoting ingredients, particularly ingredients known to have benefits for the cardiovascular system. Non-limiting examples are PUFAs, polyphenols, lipid-soluble antioxidants (e.g.
tocopherol, tocotrienols, lycopene), water-soluble antioxidants (e.g.
ascorbate), amino acids, dietary fibers, vitamins, minerals and the like.
Pharmaceutical, food or beverage products incorporating water-dispersed phytosterols can be consumed safely by anyone, but conveniently form part of the diet of those with a propensity to having high blood cholesterol levels. According to one aspect of the invention a method is provided for preventing or treating high blood cholesterol levels comprising administering, to a person in need of such treatment, a composition having an aqueous phase comprising a stable dispersion of a phytosterol and a phospholipid emulsifier having a HLB value ~ 7, wherein the weight ratio of phytosterol:phospholipid emulsifier in the aqueous phase is >1, and the combined HLB value of the phospholipid emulsifier and the phytosterol in the aqueous phase does not exceed 8. By "high blood cholesterol" is meant:
over 200mg/dl, especially over 240mg cholesterol/dl blood; and/or a ratio total cholesterollHDL of 5:1 or greater; and/or an LDL blood concentration of greater than 130mg/dl, especially over 160mg/dl. The pharmaceutical and nutritional products of the invention play a role in reducing blood cholesterol levels and thereby preventing cardiovascular disease and heart disease.
Aside from hypercholesterolemia, other indications for which phytosterols may deliver a health benefit include: hypertriglyceridemia, coronary heart disease, diabetes, atherosclerosis, inflammation, osteoarthritis, breast cancer, colon cancer, and benign prostatic hyperplasia. Therefore the invention also provides a method of preventing or treating elevated blood cholesterol levels, hypertriglyceridemia, coronary heart disease, diabetes, atherosclerosis, Alzheimer's disease, inflammation, osteoarthritis, breast cancer, colon cancer, or benign prostatic hyperplasia comprising administering, to a person in need of such treatment, any composition of the invention as defined hereinbefore.
Examples Example 1: Properties ofi aqueous ~hvtosterol dispersions made with dififerent emulsifiiers Aqueous dispersions were prepared having the compositions set out in Table I.
Table 1 Component wt Water 82 Phytosterols 10 blend Bodying agent 4.6 Thickener (or 1.2 water) Milk protein 0.9 Acidifying agent0.09 Salt 0.3 Preservative 0.12 Emulsifier (or 0.69 water) The emulsifiers tested were Emultop (Lucas Meyer), Bolec C lecithin emulsifier of HLB
approx. 3 and Tween 60 (polysorbate) emulsifier of HLB approx. 15.
In each case all of the powder ingredients (including the emulsifiers Emultop and Tween 60, but excluding Bolec C) were mixed together before blending with water at 85° C using a high shear mixer. As Bolec C has a low affinity for water it was added last to the aqueous mix of other ingredients.
For testing the mouthfeel (bitterness, texture, sandiness) the dispersions were maintained at room temperature. Observations on stability were made afiter holding the mixtures for 2 hours in a graduated cylinder held in a water bath at 40°C. Viscosity was determined using a Brookfield viscometer, spindle #3, speed 60 rpm, at 40°C. Table 2 presents the results of these tests.
Table 2 Bolec C Tween Emultop None None Emulsifier (with (with (with (with (without thickener)thickener)thickener)thickener)thickener) Bitternessslight strong slight strong very slight (from (from Mouthfeel phytosterol phytosterol) and Tween) Texture very thickthin thick thick thin Sandinessslight none none none none Phase separation Stability Good Good Good Good (i5% of clear liquid at the bottom) Viscosity 900 mPa.s 120 mPa.s350 mPa.s550 mPa.sN.D.
Table 2 shows that when attempts are made to dissolve phytosterols in water with the addition of a thickener the resulting dispersion is highly viscous and has an unpleasant taste. The absence of a thickener results in phase separation.
Bolec C is a lecithin w/o emulsifier of low HLB. It can be seen from Table 2 that use of such an emusifier results in an aqueous dispersion of very high viscosity and thick texture, which also has a slightly sandy feel.
Tween 60, a high HLB emulsifier improves the viscosity of a phytosterol-containing water dispersion, but it fails to mask the unpleasant bitter taste of the phytosterols, and moreover contributes an unpleasant taste of its own.
Emultop, which is a non-sterol lecithin emulsifier used in accordance with the invention, succeeded in moderating the viscosity of the aqueous phytosterol dispersion and simultaneously reducing the bitter taste of the phytosterol. These properties are optimal for _18_ preparing edible formulations containing phytosterol which are easily manageable during processing, have a Tong shelf life, and appeal to the consumer for taste reasons as well as for health benefits.
Example 2 : Viscous properties of emulsions made according to the invention An emulsion was prepared consisting of 35% fat phase (containing a mix of vegetable oils) and 65% water phase containing phytosterols (ReducolT""; Novartis Consumer Health), alginate thickener and EmuItopT"" lecithin emulsifier (Lucas Meyer) of HLB ~8, such that the concentrations of components in the emulsion were:
blend of phytosterols 6.6 wt%
alginate thickener 0.8 wt%
Emultop emulsifier 0.15/0.30/0.60 wt%
(+ minor amounts of salt, preservatives and acidifier) It was not possible to prepare a control emulsion lacking emulsifier altogether, because the emulsions was not stable.
The viscosity of the emulsion was measured using a Brookfield viscometer DV-1,spindle size c, at 50°C following the usual method known for viscosity measurement of shear thinning fluids after 30 minutes mixing time (mixing velocity 800 rpm), at a temperature of 50°C. The results are illustrated in Table 3.
Table 3 Emultop LevelViscosity (in emulsion)(cP.s) 0.15% 5260 0.30% 4630 0.60% 3990 -1g-It is clear from this experiment that within the range 0.15-0.60%, the higher the concentration of emulsifier such as Emultop (of high HLB) the greater the reduction in viscosity of an emulsion containing phytosterols, thereby facilitating processing of the emulsion, for instance in the preparation of fat spreads.
In an analogous experiment, when Emultop was added to the fat phase instead of the water phase it was found to deliver comparable benefits in terms of lowering emulsion viscosity.
The foam content of the water phase and the emulsion were reduced by putting the Emultop in the fat phase, leading to improved product stability in the plant.
However, there was some tendency for separation of the water to occur over time. By sharing the Emultop between the fat phase and the water phase a compromise was achieved, resulting in a stable emulsion product with low foam content.
Example 3: Process for making a low-fat spread comarisina phytosterol and Emultop in the aaueous phase A low-fat spread was prepared by the procedure outlined in the flow chart in Figure 1. The water phase is prepared by heating water up to ~5°C and then all the powder ingredients are mixed in using a normal propeller. The oil phase is prepared by premixing the components at 65°C. Then both phases are mixed together in a premix tank and cycles of crystallization are carried out. Filling can be carried out manually or by automation.
The mouthfeel of the resulting spread is comparable with that of conventional low fat spreads.
The spread was found~to be stable for more than 2 months at 4°C, and up to 9 hours at 25°C (no oil exudation).
The emulsion generated in the premix tank was not excessively viscous and therefore did not clog the equipment in a manufacturing plant. An analogous emulsion made without neutralizing emulsifier was found to obstruct the pipes, leading to difficulties in pump-assisted phase transfer between tanks, and in emptying the tanks for cleaning.
The method of the present invention makes it possible to include phytosterols at effective levels in the aqueous phase of a broad range of nutritional, cosmetic and pharmaceutical products, thereby opening up new formulation opportunities, such as low fat and fat free formulations.
In the present context the generic term "sterol" or "phytosterol" is intended to encompass any member of the family of free phytosterols (non-hydrogenated) and phytostanols, and esters or other derivatives thereof, and any mixture or combination thereof.
The phytosterols used in the invention may be chemically synthesized, or may be derived from natural sources, including plant sources such as avocado, soy, rice bran, tall oil pitch or soap, shea nut, coconut, and plant oils, for example rapeseed, soya, maize, sunflower and sesame oils. Some germ oils are very rich in phytosterols, wheat germ and oats being good examples. Non-exhaustive examples of plant sterols include sitosterol, stigmasterol, campesterol, brassicasterol, desmosterol, chalinosterol, poriferasterol, avenasterol, and clionasterol, and their corresponding stanols.
The phytosterols are provided in particulate powder form for use in preparing the dispersions of the invention. Dispersion is facilitated by using finely divided phytosterols, preferably where 95% of the particles have a size (diameter) of less than 1 OOp,m, preferably less than 30p,m and most preferably less than l5p,m. Usually, the particle size distribution will be such that 90% of the particles are in the range 100nm to 35p,m, more preferably 0.2 to 20p,m, and most preferably 0.5 to l5p.m. Particle mixtures with this size range can be prepared by standard milling techniques, such as by use of an air mill, high energy hammermill, disc mill, or air filtration mill. Optionally, the phytosterol is milled in the presence of sugar, and the powdered phytosterol/sugar mix is used in the preparation of sweetened food or nutritional products.
_7_ In the finished product (an aqueous dispersion, or an emulsion comprising the aqueous dispersion) the amount of phytosterol is preferred to be between about 0.5%
and 20% by weight of the product, more preferably 1 % to 15%, and most preferably 2% to 10% by weight, for example 3 to 8% by weight. In an emulsified product, the phytosterol in the aqueous phase may constitute 1-80 wt%, more preferably from 5-50 wt%, especially 7-25%, by weight of the aqueous phase.
The terms "neutralizing emulsifier", "neutralizing non-sterol emulsifier" and "o/w emulsifier"
are used interchangeably herein.
The neutralizing non-sterol emulsifier has a HLB (Hydrophilicity-Lipophilicity Balance) value which is higher than the HLB of the phytosterol in the aqueous phase, usually in the range 6-20, preferably 7 to 12. The HLB system is a scale used for describing the characteristics of a surface-active agent. Detailed information on the HLB system and determination of HLB values can be found in the Kirk-Othmer Encyclopedia of Chemical Technology, (3'a Ed.) 8: pp 910-918, which is incorporated herein by reference. Emulsifiers having HLB
values in the range 7 to 18, especially 8 to 18, are often termed oil in water (olw) emulsifiers. W/o emulsifiers have HLB values in the range 1-9, especially 1-6.
Since HLB
numbers are additive, the overall HLB value of a blend of emulsifiers of known HLB can easily be calculated.
In general, a single non-sterol emulsifier is used to neutralize the phytosterol.
Suitable neutralizing emulsifiers for use in the invention include phosphatides of HLB at least 7 (e.g. lysophosphatides), especially phosphoglycerides such as phospholipids and lysophospholipids. Lecithin preparations (E322) of suitably high HLB are particularly preferred, and among this group lecithin preparations containing at least 90 wt%, preferably at least 95 wt%, of acetone insoluble compounds (mostly phospholipids) are preferred.
Preparations of this sort have a low triglyceride content and are obtainable by dissolving away triglycerides from an impure lecithin preparation using acetone.
EmuItopT"" (Lucas Meyer) and SternPure ETM (Stern) are suitable lecithin emulsifiers.
Preferably, the lecithin preparations used in the invention will comprise at least 3 wt%, and more preferably at least wt%, of lysolecithin. Lecithin preparations comprising lysolecithin can be prepared from lecithin (e.g. soya lecithin or yolk lecithin) by enzymatic hydrolysis using snake venom _g_ phospholipase A2. A preferred lecithin preparation is one having a HLB value of between 8 and l 0, preferably 8-8.5.
Other neutralizing emulsifiers are [HLB values in brackets]: gelatin [9.8], sorbitan monolaurate [8.6], sodium oleate [18.0), potassium oleate [20.0], methylcellulose [10.5), acacia [12.0], tragacanth [13.2], triethanolamine oleate [12.0], polyoxyethylene monooleate [11.4], polyoxyethylene monostearate [11.6), polyoxyethylene monolaurate [13.1], polysorbates/Tweens [8 to 18] (specific examples being polyoxyethylene sorbitan monostearate (Tween 60/Tween 61 ) [14.9/9.6), polyoxyethylene sorbitan monooleate (Tinreen 80/Tween 81 ) [15/10), polyoxyethylene sorbitan monolaurate (Tween 20/Tween 21 ) [16.7/13.3), polyoxyethylene sorbitan monopalmitate (Tween 40) [15.6], polyoxyethylene sorbitan trioleate [11.0)), glyceryl esters [8-13], ethoxylated monoglycerides [12-14], sugar esters [>7; e.g. 11-15), citric acid esters of mono and diglycerides, LactemT"", CitremT"', DatemT"",and so on.
According to one embodiment of the invention when the phytosterol and neutralizing emulsifier are dispersed together in an aqueous medium, the HLB of the combination of all emulsifying components (including phytosterol and neutralizing emulsifier) in the aqueous dispersion exceeds that of the phytosterol component(s), and is <_8, preferably lying in the range of about 1 to' 8, more preferably between 3 and 6.
The amount of the non-sterol emulsifier in the aqueous dispersion, as a proportion of the finished product (e.g. an emulsion), is generally between 0.01 and 1 % by weight, and most preferably about 0.5%, such as between 0.25 and 0.45%. Phytosterol is preferably in weight excess relative to the non-sterol emulsifiers) in the aqueous dispersion. The relative weight proportions of phytosterol and non-sterol neutralizing emulsifiers present in the aqueous dispersion of the invention are optionally between 4:1 and 500:1, preferably between 7:1 and 50:1, and generally between 10:1 and 30:1.
According to another embodiment of the invention the phytosterol is dispersed in an aqueous medium, and~the neutralizing emulsifier is incorporated into a lipid medium, and an emulsion is prepared by mixing both media together. In this embodiment, too, the neutralizing emulsifier counteracts the low HLB of the phytosterol and stabilizes the emulsion formed when the aqueous phase and fat phases are mixed together. The _g_ phytosterol is preferably in weight excess relative to the non-sterol neutralizing emulsifier in the emulsified product, for instance in a dry weight ratio of 4:1 to 500:1, preferably 7:1 to 50:1, and generally 10:1 to 30:1. Optionally, the neutralizing emulsifier is distributed over both phases of the emulsion, preferably in the range 1:9 to 9:1 parts by weight (fat phase content:aqueous phase content).
In a preferred embodiment of the invention the aqueous phytosterol-containing dispersion is mixed directly with a lipid composition to create a very stable emulsion having a fat phase and a water phase, the phytosterols being primarily localized to the water phase. The emulsified fat based products created in accordance with the invention may be oil-in-water (o/w, or water continuous) or water-in-oil (w/o, or oil continuous) emulsions according to which emulsifiers are selected for use in preparing the emulsion. W/o emulsions are preferred. For the manufacture of enteral pharmaceutical and nutritional products, such as edible spreads, margarines, and icings/frostings it is usual to generate a wlo emulsion.
Salad dressings and infant formulas are generally o/w type emulsions.
Preparations for external application may be either o/w or w/o emulsions. Optionally, multiple emulsions of the w/o/w or o/w/o type can also be prepared.
fn an emulsion made in accordance with the invention the weight proportion of the aqueous phase:fat phase can vary according to the intended application of the emulsion. For edible compositions this ratio usually varies between 1:8 and 8:1. Regular yellow fat spreads and margarines contain up to 85% by weight of fat. Low fat spreads may contain 45-65% fat.
Very low fat spreads comprise 30% fat or lower. For regular salad dressings the level of fat is generally from 10-60%, more preferably from 15-40% by weight of the product. Low fat salad dressings can contain as tittle as 0-10% by weight of lipids.
In the emulsified products of the invention the fat phase preferably comprises one or more vegetable oils, such as sunflower oil, soybean oil, rapeseed oil, canola oil, corn oil, peanut/groundnut oil and the like. Dairy and other animal fat may also be used, Other lipid substances in the fat phase can include petroleum-derived waxes and oils. If desired the fat may be hydrogenated, fractionated and/or interesterified. For edible compositions it is preferred for the fat in the fat phase to comprise polyunsaturated fatty acids, PUFAs preferably contributing at least 30%, or more preferably at least 45%, of the fat phase by weight. Natural oils rich in PUFAs are the preferred source, some examples being sunflower, rapeseed, linseed, linola and/or soybean oils.
An advantage of the present invention is that it circumvents the need to add a wlo emulsifier to the fat phase of an oil continuous product, which is standard practice in commercial manufacturing of such products. The partially-neutralized inherent wlo emulsifying activity of the phytosterol aqueous phase suffices to create a stable w/o emulsion. Therefore, in one embodiment of the invention w/o emulsifiers are omitted from the lipid phase in the formation of an oil continuous fat-based product.
In certain circumstances emulsifiers may be employed in the fat phase, optionally in addition to the neutralizing phospholipid emulsifier, for example where an olw emulsion is prepared. Additional emulsifiers can include: anionic surfactants such as alcohol ether sulfates, alkyl sulfates, soaps and sulfosuccinates, sodium dodecyl sulfate (SDS), mono and diacylglycerides and derivatives thereof, e.g. AcetemT"", LactemT"", CitremT"", DatemT"";
cationic surfactants such as quaternary ammonium compounds; zwitterionic surfactants such as alkyl betaine derivatives; amphoteric surfactants such as fatty amine sulfates, difatty alkyl triethanolamine derivatives, phospholipids, lecithins, lysolecithins; and non-ionic surfactants such as the polyglycol ether derivatives of aliphatic or cycioaliphatic alcohols, saturated fatty acids and alkylphenols, water-soluble polyethyleneoxy adducts onto polypropylene glycol and alkyl polypropylene glycol, nonylphenol polyethoxyethanols, castor oil polyglycol ethers, polypropylene/polyethylene oxide adducts, tributylphenoxy-polyethoxyethanol, polyethylene glycol, octylphenoxy-polyethoxyethanol, lanolin alcohols, polyethoxylated (POE) alkyl phenols, POE fatty amides, POE fatty alcohol ethers, POE fatty amines, POE fatty esters, poloxamers (7-19), POE glycol monoethers (13-16), polysorbates and sorbitan esters, and glyceroglycolipids. In a preferred embodiment the fat phase of an emulsion made according to the invention comprises mono- and diglycerides.
Optionally, the emulsifier added to the fat phase is phytosterol. Thus, in accordance with the present invention it is possible to provide a finished edible composition containing large amounts of phytosterol distributed over both phases.
The amount of emulsifier required to be added to the fat phase varies according to the identity of the emulsifier, the type of emulsion, the material to be emulsified and the presence of stabilizing ingredients, but generally lies in the range 1-20% by weight of the lipid. For instance, the emulsion may comprise 0.05 to 1 %, preferably 0.05 to 0.5% by weight of mono and diglycerides. Exact amounts for particular applications can easily be determined by the skilled person. These will usually not need to be as high as levels used in conventional margarine manufacture, for instance, since their presence is only required where the emulsifying power of the partially neutralized phytosterols is insufficient to stabilize the emulsion.
As emulsion stabilizers, gelling agents, fat replacers and thickeners it is possible to use any conventional products suited for these purposes, especially those permitted for use in food products. Examples include, but are not limited to, lyophilic colloids such as polysaccharides including acacia gum, agar, alginic acid, carrageenan, guar gum, gellan gum, carob gum, konjac gum, karaya gum, tragacanth, locust bean gum, xanthan gum, cellulose gums, gel-forming starches (e.g. from corn, amaranth, oats, tapioca, rice and potato), modified food starches, polydextrose, maltodextrin, cyclodextrins, pectin, cellulose and its methylated derivatives, microcrystalline cellulose (MCC), inulin, oatrim, curdlan;
amphoterics (e.g.
gelatin); fibers; proteins or peptides (e.g. Microparticulated Protein Product MPP or whey protein-based thickeners); and synthetic or semi-synthetic polymers (e.g.
carbomer resins, cellulose ethers, carboxymethyl cellulose (CMC), carboxymethyf chitin, polyethylene glycol-n (ethylene oxide polymer H(OCH2CH2)"OH); finely divided solids iricluding clays (e.g.
attapulgite, bentonite, hectorite, kaolin, magnesium aluminium silicate and montmorillonite), microcrystalline cellulose oxides and hydroxides (e.g. aluminium hydroxide, magnesium hydroxide and silica); and cybotactic promoters/gellants including amino acids, lecithin and other phospholipids arid poloxamers.
Maltodextrin and/or alginate are the preferred stabilizers for addition to the aqueous phytosterol dispersion.
The amount of emulsion stabilizer/thickener to be included in the compositions of the invention depends on the consistency desired in the end product. Usual amounts lie in the range 0 to 30%, preferably 0.1 to 25% based on the weight of the aqueous phase of the product.
In a preferred procedure for preparing an aqueous dispersion in accordance with the invention, the phytosterol is provided in particulate, powder form and pre-mixed with other powdered ingredients (excluding the non-sterol emulsifier and any thickener), before addition of the 'pre-mix to hot water (60°C to 85°C) or other aqueous medium. The powdered non sterol (olw) emulsifier is then added to the aqueous medium containing the phytosterol.
Alternatively, the powdered phytosterol and powdered non-sterol (o/w) emulsifier are added together (e.g. as a pre-mix, or simultaneously) to the heated aqueous medium.
Once all the emulsifying ingredients are well dispersed it is possible to add thickening agents to the mix.
Addition of the phytosterols to the aqueous medium should be slow. Other optional components of the aqueous medium include gelling agents, fat replacers, and the like. The phytosterol-emulsifier complex in the aqueous medium is prepared by vigorous mixing, such as high shear mixing, e.g. by stirring, by turbine agitation, by propeller agitation, by microfluidization, by use of a centrifugal pump in standard Ventouri equipment, by use of a colloid mill or ball mill, by homogenization, by vortexing, by sonicating or by passing through a small orifice (e.g. in a French press).
Preferably, the aqueous medium comprising phytosterol and non-sterol (o/w) emulsifier is maintained at a temperature of between 60 and 100°C, generally about 80°C, and stirred until the phytosterol is evenly dispersed. At this point a milky suspension is obtained. The dispersion is kept under continuous agitation and, optionally, further water-soluble or water-dispersible ingredients are added to the suspension at this point: for example milk powder or protein, vegetable protein, colorings, flavorings, acidulants, preservatives, vitamins, salts, and so on. The aqueous phytosterol dispersion/suspension is phase-stable. This generally means, for example, that no phase separation is visible after at least 5 minutes, preferably after at least 30 minutes, and more preferably after at least 2 hours.
The aqueous dispersion may be used as such in preparing any liquid food, beverage, topical formulation or medicament. Alternatively the aqueous dispersion may be dried, for example by lyophilization or spray-drying, and then used in powdered form in a variety of applications.
In another embodiment of the invention the aqueous dispersion is employed (usually without an intermediate drying step) in the manufacture of an emulsified product comprising a fat phase and a water phase. W/o or o/w emulsions of this type can be prepared by any technique known in the art.
When the non-sterol neutralizing emulsifier is to be added to the fat phase of an emulsion it is melted into the fat blend that contains all the other fat ingredients, which is subsequently mixed with a phytosterol-containing aqueous phase (optionally prepared as described above).
According to a preferred process an aqueous dispersion of phytosterol (with or without the neutralizing non sterol emulsifier) is mixed with pre-heated lipid (oil or fat). Preheating is carried out at 50-60°C (preferably about 55°C). The pre-heated lipid comprises the non-sterol neutralizing emulsifier of the invention if none is already present in the aqueous dispersion or in addition to that added to the aqueous dispersion, and sometimes other emulsifiers which are lipid-soluble, such as lecithin, monoglycerides and diglycerides. An emulsion is created by mixing together the aqueous blend with the fat blend.
Further processing of the emulsion depends on the intended use of the emulsion. In the preparation of margarines, spreads and the like, the emulsifying step is followed by pasteurization, crystallisation and filling, which are standard procedures in,the art.
The lipid used to make the emulsions may comprise additional fat-soluble components which are customary additives in the art, for example stabilizers, coloring agents, flavoring agents, pH regulators, vitamins (e.g. vitamins A & D), salts, anti-bacterial agents, antioxidants and preservatives. In the case of spreads and margarines the preferred antioxidants are tocopherols.
Emulsified w/o products made by the preparative method of the invention are particularly phase stable and can be stored and transported under demanding conditions without exhibiting a tendency to separate.
The nutritional product formats which are envisaged to incorporate the aqueous dispersion of the invention include: emulsified fat spreads or margarine, shortenings, cheese, mayonnaise, ice-cream, salad dressing, yoghurt, smoothies, chocolate, puddings, dairy desserts, coffee whitener, custards, dairy beverages, milk-shakes, icings, baked products, cake mixes, noodles, pasta, granola bars, soups, infant formulas, and the like.
Medical nutrition products comprising the dispersion of the invention include enteral and parenteral complete formula diets, in liquid form or lyophilized for later reconstitution, and medical feeding supplements. Products formulated for enteral feeding may be intended for tube feeding or for oral administration, either in hospitals or in the home.
The medical nutrition products may be formulated having regard to the needs of particular patient types, such as diabetics, heart disease patients, stroke patients, arthritis sufferers, cancer patients, and anyone at risk of developing these diseases.
The nutritional products according to the invention may be non-fat products, low fat products or very low fat products. By "tow fat" is generally meant a product, such as a yellow fat spread, comprising less than 45% (e.g. 35-40%), preferably less than 35%, by weight fat. A "very low fat" product has less than 30% by weight fat.
This invention makes possible the provision of phytosterols in oral pharmaceutical dosage forms, particularly solid forms; including tablets, capsules, dragees, granules, pellets, chews, solutions, syrups, lozenges, and powders. Parenteral emulsions can also be prepared for administration to severely-debilitated patients. Customary pharmaceutical excipients, diluents and stabilizers may be employed.
Topical cosmetic and pharmaceutical formulations incorporating the emulsions of the invention include salves, creams, foams, lotions, gels, soaps, shampoos, and the like.
The pharmaceutical,~food or drink products may be supplemented with other health-promoting ingredients, particularly ingredients known to have benefits for the cardiovascular system. Non-limiting examples are PUFAs, polyphenols, lipid-soluble antioxidants (e.g.
tocopherol, tocotrienols, lycopene), water-soluble antioxidants (e.g.
ascorbate), amino acids, dietary fibers, vitamins, minerals and the like.
Pharmaceutical, food or beverage products incorporating water-dispersed phytosterols can be consumed safely by anyone, but conveniently form part of the diet of those with a propensity to having high blood cholesterol levels. According to one aspect of the invention a method is provided for preventing or treating high blood cholesterol levels comprising administering, to a person in need of such treatment, a composition having an aqueous phase comprising a stable dispersion of a phytosterol and a phospholipid emulsifier having a HLB value ~ 7, wherein the weight ratio of phytosterol:phospholipid emulsifier in the aqueous phase is >1, and the combined HLB value of the phospholipid emulsifier and the phytosterol in the aqueous phase does not exceed 8. By "high blood cholesterol" is meant:
over 200mg/dl, especially over 240mg cholesterol/dl blood; and/or a ratio total cholesterollHDL of 5:1 or greater; and/or an LDL blood concentration of greater than 130mg/dl, especially over 160mg/dl. The pharmaceutical and nutritional products of the invention play a role in reducing blood cholesterol levels and thereby preventing cardiovascular disease and heart disease.
Aside from hypercholesterolemia, other indications for which phytosterols may deliver a health benefit include: hypertriglyceridemia, coronary heart disease, diabetes, atherosclerosis, inflammation, osteoarthritis, breast cancer, colon cancer, and benign prostatic hyperplasia. Therefore the invention also provides a method of preventing or treating elevated blood cholesterol levels, hypertriglyceridemia, coronary heart disease, diabetes, atherosclerosis, Alzheimer's disease, inflammation, osteoarthritis, breast cancer, colon cancer, or benign prostatic hyperplasia comprising administering, to a person in need of such treatment, any composition of the invention as defined hereinbefore.
Examples Example 1: Properties ofi aqueous ~hvtosterol dispersions made with dififerent emulsifiiers Aqueous dispersions were prepared having the compositions set out in Table I.
Table 1 Component wt Water 82 Phytosterols 10 blend Bodying agent 4.6 Thickener (or 1.2 water) Milk protein 0.9 Acidifying agent0.09 Salt 0.3 Preservative 0.12 Emulsifier (or 0.69 water) The emulsifiers tested were Emultop (Lucas Meyer), Bolec C lecithin emulsifier of HLB
approx. 3 and Tween 60 (polysorbate) emulsifier of HLB approx. 15.
In each case all of the powder ingredients (including the emulsifiers Emultop and Tween 60, but excluding Bolec C) were mixed together before blending with water at 85° C using a high shear mixer. As Bolec C has a low affinity for water it was added last to the aqueous mix of other ingredients.
For testing the mouthfeel (bitterness, texture, sandiness) the dispersions were maintained at room temperature. Observations on stability were made afiter holding the mixtures for 2 hours in a graduated cylinder held in a water bath at 40°C. Viscosity was determined using a Brookfield viscometer, spindle #3, speed 60 rpm, at 40°C. Table 2 presents the results of these tests.
Table 2 Bolec C Tween Emultop None None Emulsifier (with (with (with (with (without thickener)thickener)thickener)thickener)thickener) Bitternessslight strong slight strong very slight (from (from Mouthfeel phytosterol phytosterol) and Tween) Texture very thickthin thick thick thin Sandinessslight none none none none Phase separation Stability Good Good Good Good (i5% of clear liquid at the bottom) Viscosity 900 mPa.s 120 mPa.s350 mPa.s550 mPa.sN.D.
Table 2 shows that when attempts are made to dissolve phytosterols in water with the addition of a thickener the resulting dispersion is highly viscous and has an unpleasant taste. The absence of a thickener results in phase separation.
Bolec C is a lecithin w/o emulsifier of low HLB. It can be seen from Table 2 that use of such an emusifier results in an aqueous dispersion of very high viscosity and thick texture, which also has a slightly sandy feel.
Tween 60, a high HLB emulsifier improves the viscosity of a phytosterol-containing water dispersion, but it fails to mask the unpleasant bitter taste of the phytosterols, and moreover contributes an unpleasant taste of its own.
Emultop, which is a non-sterol lecithin emulsifier used in accordance with the invention, succeeded in moderating the viscosity of the aqueous phytosterol dispersion and simultaneously reducing the bitter taste of the phytosterol. These properties are optimal for _18_ preparing edible formulations containing phytosterol which are easily manageable during processing, have a Tong shelf life, and appeal to the consumer for taste reasons as well as for health benefits.
Example 2 : Viscous properties of emulsions made according to the invention An emulsion was prepared consisting of 35% fat phase (containing a mix of vegetable oils) and 65% water phase containing phytosterols (ReducolT""; Novartis Consumer Health), alginate thickener and EmuItopT"" lecithin emulsifier (Lucas Meyer) of HLB ~8, such that the concentrations of components in the emulsion were:
blend of phytosterols 6.6 wt%
alginate thickener 0.8 wt%
Emultop emulsifier 0.15/0.30/0.60 wt%
(+ minor amounts of salt, preservatives and acidifier) It was not possible to prepare a control emulsion lacking emulsifier altogether, because the emulsions was not stable.
The viscosity of the emulsion was measured using a Brookfield viscometer DV-1,spindle size c, at 50°C following the usual method known for viscosity measurement of shear thinning fluids after 30 minutes mixing time (mixing velocity 800 rpm), at a temperature of 50°C. The results are illustrated in Table 3.
Table 3 Emultop LevelViscosity (in emulsion)(cP.s) 0.15% 5260 0.30% 4630 0.60% 3990 -1g-It is clear from this experiment that within the range 0.15-0.60%, the higher the concentration of emulsifier such as Emultop (of high HLB) the greater the reduction in viscosity of an emulsion containing phytosterols, thereby facilitating processing of the emulsion, for instance in the preparation of fat spreads.
In an analogous experiment, when Emultop was added to the fat phase instead of the water phase it was found to deliver comparable benefits in terms of lowering emulsion viscosity.
The foam content of the water phase and the emulsion were reduced by putting the Emultop in the fat phase, leading to improved product stability in the plant.
However, there was some tendency for separation of the water to occur over time. By sharing the Emultop between the fat phase and the water phase a compromise was achieved, resulting in a stable emulsion product with low foam content.
Example 3: Process for making a low-fat spread comarisina phytosterol and Emultop in the aaueous phase A low-fat spread was prepared by the procedure outlined in the flow chart in Figure 1. The water phase is prepared by heating water up to ~5°C and then all the powder ingredients are mixed in using a normal propeller. The oil phase is prepared by premixing the components at 65°C. Then both phases are mixed together in a premix tank and cycles of crystallization are carried out. Filling can be carried out manually or by automation.
The mouthfeel of the resulting spread is comparable with that of conventional low fat spreads.
The spread was found~to be stable for more than 2 months at 4°C, and up to 9 hours at 25°C (no oil exudation).
The emulsion generated in the premix tank was not excessively viscous and therefore did not clog the equipment in a manufacturing plant. An analogous emulsion made without neutralizing emulsifier was found to obstruct the pipes, leading to difficulties in pump-assisted phase transfer between tanks, and in emptying the tanks for cleaning.
Claims (25)
1. A method of preparing a product comprising phytosterol dispersed in an aqueous phase, which comprises mixing particulate phytosterol with an aqueous phase in the presence of a non-sterol emulsifier having a HLB value higher than that of the phytosterol to create an aqueous phytosterol dispersion, such that the combined HLB value of the non-sterol emulsifier and the phytosterol in the aqueous phase does not exceed 8.
2. A method according to claim 1 wherein said non-sterol emulsifier has a HLB
value of at least 7.
value of at least 7.
3. A method of preparing an emulsified product comprising phytosterol dispersed in an aqueous phase, which comprises mixing particulate phytosterol with an aqueous phase, adding a non-sterol emulsifier having a HLB value of at least 7 to the aqueous phase and/or to a fat phase, and mixing together the aqueous phase and the fat phase to form an emulsion.
4. A method according to any preceding claim wherein said non-sterol emulsifier comprises phospholipid.
5. A method according to claim 4 wherein said phospholipid comprises lysolecithin.
6. A method according to any preceding claim wherein the particulate phytosterol is added to the aqueous phase prior to, or simultaneous with, addition of the non-sterol emulsifier to the aqueous phase.
7. A method according to any preceding claim wherein 95% of the particles in the particulate phytosterol have a size of between 0.5 and 15µm.
8. A method according to any preceding claim wherein a thickener, such as maltodextrin and/or alginate, is added to the aqueous phase.
9. A composition obtainable by the method of any of claims 1 to 8.
10. A composition having an aqueous phase comprising a stable dispersion of a phytosterol and a phospholipid emulsifier having a HLB value >= 7, wherein the weight ratio of phytosterol:phospholipid emulsifier in the aqueous phase is 1:1, and the combined HLB
value of the phospholipid emulsifier and the phytosterol in the aqueous phase does not exceed 8.
value of the phospholipid emulsifier and the phytosterol in the aqueous phase does not exceed 8.
11. A composition according to claim 10 which further comprises a fat phase.
12. An emulsified composition having an aqueous phase comprising a phytosterol and a fat phase comprising a phospholipid emulsifier having a HLB value >= 7.
13. An emulsified composition according to claim 12 which further comprises said phospholipid emulsifier in the aqueous phase of the composition.
14. A composition according to any of claims 10 to 13 wherein the phytosterol comprises non-hydrogenated free phytosterols or esters thereof, or mixtures thereof.
15. A composition according to any of claims 10 to 14 wherein the phospholipid emulsifier is a lecithin preparation.
16. A composition according to claim 15 wherein the lecithin preparation comprises at least 3 % by weight lysolecithin.
17. A composition according to any of claims 10 to 16, wherein the phospholipid emulsifier is present in an amount of 0.01 to 25% by weight of the phytosterol.
18. A composition according to any of claims 10 to 17 wherein said aqueous phase further comprises one or more thickening/gelling agents selected from the group consisting of alginate, gelatin and maltodextrin.
19. A composition according to any of claims 11 to 18 which comprises a water-in-oil emulsion.
20. A composition according to any of claims 10 to 19 which is a nutritional product selected from the group consisting of: an emulsified fat spread or margarine, mayonnaise, ice-cream, salad dressing, yoghurt, chocolate, puddings, dairy desserts, coffee whitener, dairy beverages, icings, and medical nutrition products,
21. A composition according to claim 20 which is a low fat or very low fat nutritional product.
22. Use of a neutralizing emulsifier to reduce the viscosity of an aqueous dispersion of phytosterol or of an emulsion comprising said aqueous dispersion, particularly where said dispersion comprises a thickening agent.
23. Use of a neutralizing emulsifier to stabilize an emulsion comprising a fat phase and an aqueous phase comprising phytosterol, wherein the neutralizing emulsifier is in the aqueous phase or in the fat phase or distributed between the aqueous phase and the fat phase.
24. A composition according to any of claims 10 to 21 for use as a medicament.
25. Use of a composition according to any of claims 10 to 21 in the manufacture of a medicament or therapeutic nutritional formulation for the prevention or treatment of any of:
elevated blood cholesterol levels, hypertriglyceridemia, coronary heart disease, diabetes, atherosclerosis, Alzheimer's disease, inflammation, osteoarthritis, breast cancer, colon cancer, and benign prostatic hyperplasia.
elevated blood cholesterol levels, hypertriglyceridemia, coronary heart disease, diabetes, atherosclerosis, Alzheimer's disease, inflammation, osteoarthritis, breast cancer, colon cancer, and benign prostatic hyperplasia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0104074.0A GB0104074D0 (en) | 2001-02-19 | 2001-02-19 | New composition |
GB0104074.0 | 2001-02-19 | ||
PCT/EP2002/001715 WO2002065859A1 (en) | 2001-02-19 | 2002-02-18 | Emulsions and aqueous dispersions of phytosterols |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2438519A1 true CA2438519A1 (en) | 2002-08-29 |
Family
ID=9909052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002438519A Abandoned CA2438519A1 (en) | 2001-02-19 | 2002-02-18 | Emulsions and aqueous dispersions of phytosterols |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1363508A1 (en) |
JP (1) | JP2004519232A (en) |
BR (1) | BR0207374A (en) |
CA (1) | CA2438519A1 (en) |
GB (1) | GB0104074D0 (en) |
HU (1) | HUP0400749A2 (en) |
MX (1) | MXPA03007419A (en) |
PL (1) | PL363289A1 (en) |
WO (1) | WO2002065859A1 (en) |
ZA (1) | ZA200306161B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020026053A (en) * | 2000-09-30 | 2002-04-06 | 노승권 | Method of dispersing plant sterol for a beverage and beverage containing the same |
CA2481705A1 (en) * | 2002-04-10 | 2003-10-23 | Thomas P. Binder | Hydrothermically processed compositions containing phytosterols |
IL155136A0 (en) * | 2003-02-10 | 2003-10-31 | Enzymotec Ltd | A composition for reducing blood cholesterol and triglycerides |
US20060233863A1 (en) | 2003-02-10 | 2006-10-19 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy |
EP1946644A3 (en) | 2003-12-04 | 2009-11-18 | Unilever N.V. | Shelf stable homogeneous suspension |
US20060035009A1 (en) * | 2004-08-10 | 2006-02-16 | Kraft Foods Holdings, Inc. | Compositions and processes for water-dispersible phytosterols and phytostanols |
EP1796726A2 (en) | 2004-08-10 | 2007-06-20 | Enzymotec Ltd. | Mixture of phytosterol ester(s) and 1,3-diglyceride(s) for use in the treatment of medical conditions |
US8057837B2 (en) * | 2004-10-07 | 2011-11-15 | General Mills, Inc. | Microwave popcorn with viscous liquid fat and method of preparation |
KR20070086083A (en) * | 2004-11-17 | 2007-08-27 | 산에이겐 에후.에후. 아이. 가부시키가이샤 | Sitosterol compound-containing composition and process for producing the same |
EP1859682A4 (en) * | 2005-02-24 | 2010-07-07 | San Ei Gen Ffi Inc | Vegetable sterol-containing milk drink and method of producing the same |
JP2009519721A (en) * | 2005-12-20 | 2009-05-21 | フォーブス メディ−テック インコーポレーテッド | A composition comprising one or more phytosterols and / or phytostanols, or derivatives thereof, and a high HLB emulsifier. |
US20110268846A1 (en) | 2006-03-13 | 2011-11-03 | Malathy Nair | Steeped cocoa compositions and functional cocoa beverages made from them |
US20080038409A1 (en) | 2006-03-13 | 2008-02-14 | Malathy Nair | Steeped cocoa compositions and functional cocoa beverages made from them |
KR100816052B1 (en) | 2006-04-28 | 2008-03-21 | 주식회사 삼양제넥스 | Composition containing water-dispersed phytosterol ester |
EP2067410A1 (en) | 2007-12-07 | 2009-06-10 | Cognis IP Management GmbH | Water-dispersable sterol containing dispersion |
CN102186341B (en) | 2008-10-20 | 2013-12-25 | 荷兰联合利华有限公司 | Antimicrobial composition |
CL2009000409A1 (en) * | 2009-02-23 | 2009-05-04 | Rojas Alejandro Markovits | Process to obtain a dispersion of solid phytosterols in water. |
EA019746B1 (en) | 2009-09-24 | 2014-05-30 | Юнилевер Нв | Disinfecting agent comprising eugenol, terpineol and thymol and method of disinfecting a surface |
WO2011095305A1 (en) * | 2010-02-06 | 2011-08-11 | Cognis Ip Management Gmbh | Drink |
US20120135970A1 (en) * | 2010-11-29 | 2012-05-31 | Raisio Nutrition Ltd. | Compositions for preventing and treating an immune system disorder |
US9603858B2 (en) * | 2010-11-29 | 2017-03-28 | Raisio Nutrition Ltd. | Compositions for preventing and treating an immune system disorder |
EA022986B1 (en) | 2010-12-07 | 2016-04-29 | Юнилевер Нв | Oral care composition |
CN103998011B (en) | 2011-11-03 | 2016-11-23 | 荷兰联合利华有限公司 | Personal cleaning compositions |
FI125947B (en) | 2013-07-05 | 2016-04-29 | Ravintoraisio Oy | Blood cholesterol lowering composition |
WO2015131995A1 (en) * | 2014-03-03 | 2015-09-11 | Raisio Nutrition Ltd | Serum cholesterol lowering edible product |
CN115918906A (en) * | 2023-01-10 | 2023-04-07 | 丰益油脂科技有限公司 | Method for efficiently preparing water-dispersible phytosterol particles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3221579A1 (en) * | 1982-06-08 | 1983-12-22 | Eckert, Theodor, Prof. Dr., 4400 Münster | Solubilisation of active substances, which are sparingly soluble in water, in aqueous solution using a mixture of cholinephosphoric acid glycerol diester (choline-lecithin) and sodium deoxycholate as solubiliser, and the therapeutic use of the aqueous solutions obtained thereby |
DE4038385C2 (en) * | 1990-12-01 | 1998-09-17 | Hoyer Gmbh & Co Kg | Sitosterol and its glycosides with improved bioavailability |
US6423363B1 (en) * | 1997-08-22 | 2002-07-23 | Lipton, Division Of Conopco, Inc. | Aqueous dispersion |
IN185730B (en) * | 1998-02-19 | 2001-04-14 | Mcneil Ppc Inc | |
BR9904796B1 (en) * | 1998-03-24 | 2012-02-22 | phytosterol-containing oil or fat composition, oil or fat composition, food product, beverage product, and cooking table oil. | |
NZ508645A (en) * | 1998-06-05 | 2003-10-31 | Forbes Medi Tech Inc | Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability and the use of these compositions to lower serum cholesterol |
US6677327B1 (en) * | 1999-11-24 | 2004-01-13 | Archer-Daniels-Midland Company | Phytosterol and phytostanol compositions |
-
2001
- 2001-02-19 GB GBGB0104074.0A patent/GB0104074D0/en not_active Ceased
-
2002
- 2002-02-18 MX MXPA03007419A patent/MXPA03007419A/en unknown
- 2002-02-18 CA CA002438519A patent/CA2438519A1/en not_active Abandoned
- 2002-02-18 HU HU0400749A patent/HUP0400749A2/en unknown
- 2002-02-18 WO PCT/EP2002/001715 patent/WO2002065859A1/en active Application Filing
- 2002-02-18 JP JP2002565434A patent/JP2004519232A/en active Pending
- 2002-02-18 BR BR0207374-9A patent/BR0207374A/en not_active IP Right Cessation
- 2002-02-18 EP EP02719865A patent/EP1363508A1/en not_active Withdrawn
- 2002-02-18 PL PL02363289A patent/PL363289A1/en not_active Application Discontinuation
-
2003
- 2003-08-08 ZA ZA200306161A patent/ZA200306161B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2004519232A (en) | 2004-07-02 |
GB0104074D0 (en) | 2001-04-04 |
WO2002065859A1 (en) | 2002-08-29 |
PL363289A1 (en) | 2004-11-15 |
MXPA03007419A (en) | 2003-11-18 |
HUP0400749A2 (en) | 2004-08-30 |
ZA200306161B (en) | 2004-08-02 |
EP1363508A1 (en) | 2003-11-26 |
BR0207374A (en) | 2004-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2438519A1 (en) | Emulsions and aqueous dispersions of phytosterols | |
EP1197153B2 (en) | Aqueous dispersions or suspensions | |
EP1315482B1 (en) | Water-dispersible encapsulated sterols | |
AU2006201678B2 (en) | Stabilized dispersion of phytosterol in oil | |
JP5630770B2 (en) | Phytosterol dispersion | |
JP2008143843A (en) | Pulverized phytosterol ester preparation, method for producing the same and food and drink containing the same | |
EP1968605A1 (en) | Emulsions comprising non-esterified phytosterols in the aqueous phase | |
AU2005234649B2 (en) | Water-dispersible encapsulated sterols | |
EP1501367B1 (en) | Food product comprising a phytosterol | |
AU2002250969A1 (en) | Emulsions and aqueous dispersions of phytosterols | |
AU2006202608A1 (en) | Emulsions and aqueous dispersions of phytosterols | |
EP2744355B1 (en) | Edible composition comprising sterol | |
US20110223312A1 (en) | Triglyceride-encapsulated phytosterol microparticles dispersed in beverages | |
AU2002317786A1 (en) | Stabilized dispersion of phytosterol in oil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |